Poseidon reaps success for AstraZeneca’s Imfinzi in non-small cell lung cancer
The trial will continue to assess the additional primary endpoint of overall survival, with data anticipated in 2020.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more